donepezil hydrochloride

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Jun 10, 2010 → Jun 23, 2016

NCT ID

NCT01129596

About donepezil hydrochloride

donepezil hydrochloride is a pre-clinical stage product being developed by Eisai for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01129596. Target conditions include Alzheimer's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer's Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02448784	Pre-clinical	Completed	Apr 20, 2015	Mar 30, 2017	Dementia With Lewy Body Disease
NCT02162264	Pre-clinical	Completed	Jun 1, 2013	Jul 22, 2016	Alzheimer's Disease
NCT02162251	Pre-clinical	Completed	Jun 1, 2013	Apr 15, 2016	Alzheimer's Desease
NCT01251718	Pre-clinical	Completed	Dec 1, 2010	Feb 18, 2016	Alzheimer's Disease
NCT01129596	Pre-clinical	Completed	Jun 10, 2010	Jun 23, 2016	Alzheimer's Disease
NCT00477659	Approved	Completed	Jul 23, 2007	Aug 15, 2008	Alzheimer's Disease
NCT00165750	Approved	Terminated	Mar 1, 2005	Nov 1, 2008	Alzheimer's Disease
NCT00165724	Approved	Completed	Jun 30, 2004	Dec 31, 2006	Alzheimer's Disease
NCT00165737	Phase 3	Completed	Mar 1, 2003	Jun 1, 2006	Dementia, Vascular
NCT00165659	Phase 2	Completed	Nov 1, 2002	—	Alzheimer Disease
NCT00096473	Phase 3	Completed	Jan 1, 2001	Sep 1, 2005	Alzheimer's Disease

Competing Products

20 competing products in Alzheimer's Disease

See all competitors

Product	Company	Stage	Hype Score
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
GSK4527226	Alector	Phase 2	29
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
simufilam	Cassava Sciences	Phase 2	17
Remternetug + Placebo	Eli Lilly	Phase 3	44
solanezumab	Eli Lilly	Phase 2	35
LY2886721 + Placebo	Eli Lilly	Phase 1	29
Gantenerumab + Gantenerumab + Gantenerumab + Placebo	Chugai Pharmaceutical	Phase 1	29
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.	Yuhan	Approved	39
FK962	Astellas Pharma	Phase 2	27
ASP0777 + Placebo	Astellas Pharma	Phase 1	29
Elenbecestat + Placebo	Eisai	Phase 3	32
Donepezil	Eisai	Approved	43
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)	Eisai	Phase 3	40
Donepezil hydrochloride	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Pre-clinical	26